Item 8.01. Other Events.

On April 8, 2022, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company has paused enrollment in clinical trials with BCX9930 while it investigates elevated serum creatinine levels seen in some patients. Patients currently enrolled in the trials are continuing on study drug at this time. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



Exhibit No.       Description

  99.1              Press release dated April 8, 2022 entitled "BioCryst Pauses
                  Enrollment in BCX9930 Clinical Trials"
104               Cover Page Interactive Data File (embedded within the Inline
                  XBRL document)

© Edgar Online, source Glimpses